Company History

King Pharmaceuticals® began operations in January 1994, after purchasing the company’s Bristol Tennessee facility and assuming contracts to manufacture prescription pharmaceutical products for such prominent companies as SmithKline Beecham Corporation, predecessor to GlaxoSmithKline, and Novartis.

For the next ten years, King principally focused on the manufacture, acquisition and marketing of previously approved products. Under new leadership in 2004, the company shifted strategy to become a leading developer and acquirer of novel branded pharmaceutical products in later stages of development. Recently, the Company began accelerating its plan to emphasize its neuroscience, hospital and acute care medicine platforms to capitalize on its core strengths in and positive dynamics of these marketplaces.

King’s labor force has grown from an initial 145 to over 2,600 employees involved in every discipline of a major pharmaceutical company, including sales and marketing, research and development, medical affairs, regulatory affairs, quality management and manufacturing.

King’s revenues have grown from $13 million in 1994 to over $1.78 billion in 2009. King’s common stock trades on the New York Stock Exchange under the symbol “KG,” and is a component of the S&P 500 Index and the AMEX pharmaceutical index.

Relying on talented and dedicated employees, following a strategic vision and developing trusted relationships with other drug companies, wholesalers, physicians and pharmacists, King is redefining the standards for success in pursuing opportunities in the health care industry.